Recombinant human erythropoietin: Has treatment reached its full potential?

Seminars in Dialysis

Volumn 19, Issue 1, 2006, Pages 1-4

  Fishbane, Steven ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ERYTHROPOIESIS; HUMAN; PHYSIOLOGY; REVIEW;

ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS;

EID: 33645338994     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00109.x     Document Type: Review

References (29)

1. Horl WH Erythropoietin and renal anemia. Biotechnol Ther 2 213 230 1991
2. Collins AJ Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl 80 44 48 2002
3. Besarab A Bolton WK Browne JK Egrie JC Nissenson AR Okamoto DM Schwab SJ Goodkin DA The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 584 590 1998
4. Foley RN Parfrey PS Morgan J Barre PE Campbell P Cartier P Coyle D Fine A Handa P Kingma I Lau CY Levin A Mendelssohn D Muirhead N Murphy B Plante RK Posen G Wells GA Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 1325 1335 2000
5. Furuland H Linde T Ahlmen J Christensson A Strombom U Danielson BG A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 353 361 2003
6. Roger SD McMahon LP Clarkson A Disney A Harris D Hawley C Healy H Kerr P Lynn K Parnham A Pascoe R Voss D Walker R Levin A Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15 148 156 2004
7. Jelkmann W Hellwig-Burgel T Biology of erythropoietin. Adv Exp Med Biol 502 169 187 2001
8. Jelkmann W Molecular biology of erythropoietin. Intern Med 43 649 659 2004
9. Maxwell PH Ferguson DJ Nicholls LG Iredale JP Pugh CW Johnson MH Ratcliffe PJ Sites of erythropoietin production. Kidney Int 51 393 401 1997
10. Jelkmann W Biochemistry and assays of EPO. In Jelkmann W (ed). Erythropoietin: Molecular Biology and Clinical Use.
11. Semenza GL Agani F Iyer N Jiang BH Leung S Wiener C Yu A Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest 114 1 suppl 40S 45S 1998
12. Testa U Apoptotic mechanisms in the control of erythropoiesis. Leukemia 18 1176 1199 2004
13. McMahon FG Vargas R Ryan M Jain AK Abels RI Perry B Smith IL Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76 1718 1722 1990
14. Kaufmann JS Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 32 suppl 4 S147 S151 1998
15. Trial J Rice L Alfrey CP Erythropoietin withdrawal alters interactions between young red blood cellssplenic endothelial cellsand macrophages: an in vitro model of neocytolysis. J Invest Med 49 335 345 2001
16. Rice L Alfrey CP Driscoll T Whitley CE Hachey DL Suki W Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 33 59 62 1999
17. Trial J Rice L Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Des 10 183 190 2004
18. Savino R Ciliberto G A paradigm shift for erythropoietin: no longer a specialized growth factorbut rather an all-purpose tissue-protective agent. Cell Death Differ 11 suppl 1 S2 S4 2004
19. Grasso G Sfacteria A Cerami A Brines M Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 10 93 98 2004
20. Cerami A Brines ML Ghezzi P Cerami CJ Effects of epoetin alfa on the central nervous system. Semin Oncol 28 suppl 8 66 70 2001
21. Ribatti D Presta M Vacca A Ria R Giuliani R Dell'Era P Nico B Roncali L Dammacco F Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93 2627 2636 1999
22. Haroon ZA Amin K Jiang X Arcasoy MO A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163 993 1000 2003
23. Paffett-Lugassy N Zon LI Epo-EpoR signaling not required for cardiovascular or neural development [abstract]. Blood 100 2277 2002
24. Parsa CJ Kim J Riel RU Pascal LS Thompson RB Petrofski JA Matsumoto A Stamler JS Koch WJ Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 14 20655 20662 2004
25. Calvillo L Latini R Kajstura J Leri A Anversa P Ghezzi P Salio M Cerami A Brines M Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100 4802 4806 2003
26. Wright GL Hanlon P Amin K Steenbergen C Murphy E Arcasoy MO Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 1031 1033 2004
27. Xu B Dong G Liu H Wang Y Wu H Jing H Recombinant human erythropoietin pretreatment attenuates myocardial infarct size. a possible mechanism involves heat shock protein 70 and attenuation of nuclear factor-kappaβ. Ann Clin Lab Sci 35 161 168 2005
28. Fishbane S Berns JS Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 1337 1343 2005
29. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 suppl 1 S182 S238 2001